Vericel Confident in Near-Term MACI Recovery

Vericel's MACI orthobiologic

Vericel reported 1Q20 orthopedic revenue of USD $20.3 million, +22.4% vs. 1Q19. Prior to mid-March, the company was on track to achieve more than +30% growth; however, procedure cancelations due to COVID-19 reduced MACI implant volume by high single digits. MACI revenue is trending toward a revenue reduction around 50% in the second quarter,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us